Apollo Hospitals Enterprise Ltd reported a 34% year-on-year increase in net profit to ₹5.8b for the quarter ended June 30, 2026, beating the analyst estimate of ₹5.53b. Consolidated revenue grew 21% to ₹70.4b, surpassing the expected ₹69.23b, while EBITDA expanded 28% to ₹10.9b against an estimate of ₹10.4b. EBITDA margin improved to 15.51% from 15% in the year-ago period, reflecting broad-based operational strength across healthcare services and digital health platforms.

Financial performance

The following table summarises Apollo Hospitals' key consolidated financial metrics for the quarter:

The healthcare services segment, which forms the backbone of the business, delivered robust top-line growth. Revenue from this segment rose 22% to ₹35,670 crore, propelled by an 8% increase in average revenue per inpatient to ₹186,630 and a 13% jump in inpatient discharges to 171,662. Occupancy rates improved to 70% from 65% in the prior year period.

Apollo HealthCo, the digital health and pharmacy distribution arm, reported revenue of ₹29,770 crore, up 20% year-on-year. The digital cash loss narrowed to ₹97 million (excluding ESOP charges), down from ₹487 million in Q1FY26, driven by efficient user acquisition and sustained per-order profitability despite lower marketing spend.

Segment highlights

Healthcare services:

• Established units saw volume growth of 11% and revenue growth of 20%.
• Five new hospitals were commissioned in the last two quarters, adding approximately 1,000 census beds.
• Pre-operative expenses for new units totalled ₹375 million, while established unit EBITDA margins held at 25.9%.

Diagnostics and retail health (AHLL):

• AHLL revenue grew 15% to ₹4,995 crore, with EBITDA surging 46% to ₹590 million.
• Diagnostics revenue jumped 31% YoY, driven by 38% growth in the wellness segment and 41% growth in specialty tests.

What the numbers show

The divergence between revenue growth and margin expansion in the healthcare services segment highlights operational leverage. While revenue grew 22%, EBITDA grew 20%, indicating that cost structures are scaling efficiently alongside volume increases. The 30 basis point contraction in segment EBITDA margin, from 24.5% to 24.2%, is largely attributable to pre-operative expenses from newly commissioned hospitals.

Strategic developments

Apollo Hospitals continues to expand its footprint through both greenfield projects and acquisitions. Key initiatives include:

• Commissioning of five new hospitals including facilities in Pune, Hyderabad, and Kolkata.
• Launch of AI-based X-ray/RVG analysis across its dental network.
• Expansion of GLP services to additional centres and introduction of pain management longevity services.

The company also signed an MoU with ePlane Company to explore electric air ambulances and medical delivery drones, signalling a push towards integrating advanced logistics into its emergency care network.

Apollo Hospitals Enterprise Limited has scheduled its 45th Annual General Meeting (AGM) for Tuesday, August 25, 2026, to secure shareholder approval for the reappointment of Dr. Prathap C Reddy as Executive Chairman and the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹7,500 million. The meeting, conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM), also aims to ratify a final dividend of ₹10 per share and reappoint independent director Smt. Rama Bijapurkar, ensuring continuity in leadership and capital structure during the proposed demerger of Apollo Healthtech Limited.

The Board of Directors recommended Dr. Reddy’s reappointment for a two-year term from June 25, 2026, to June 24, 2028. His remuneration includes a fixed pay of ₹85.00 million per annum, variable pay linked to Key Performance Indicators (KPIs), and a commission capped at 1% of net profits before tax, with an annual maximum of ₹75 million. The Nomination & Remuneration Committee highlighted his critical role in overseeing the strategic transition associated with the Healthtech demerger.

Capital Raising and Dividend Payout

Shareholders are requested to approve the private placement of secured or unsecured redeemable NCDs up to ₹7,500 million to fund capital expenditure and general corporate purposes. This issuance falls within the company’s overall approved borrowing limit of ₹38,500 million. Specific terms, including coupon rates and redemption periods, will be determined by the Board for future tranches.

The AGM agenda includes confirming the interim dividend of ₹10 per equity share paid on February 27, 2026, and declaring a final dividend of ₹10 per equity share for FY26. The total dividend payout for the year is ₹20 per share, aggregating to ₹2,875.70 million. The record date for the final dividend is Friday, August 14, 2026, with payments due by September 10, 2026.

Director Appointments

Smt. Sangita Reddy and Dr. Prathap C Reddy retire by rotation and are eligible for reappointment. Smt. Rama Bijapurkar is proposed for reappointment as an Independent Director for a second five-year term, commencing November 12, 2026, to November 11, 2031. Her expertise in business strategy is deemed vital as the company focuses on core hospital operations post-demerger.

E-Voting and Participation Details

Remote e-voting commences on Saturday, August 22, 2026, at 9:00 A.M. IST and concludes on Monday, August 24, 2026, at 5:00 P.M. IST. National Securities Depository Limited (NSDL) serves as the authorized agency. Members holding shares as of the cut-off date, Tuesday, August 18, 2026, are eligible to vote. Physical attendance is dispensed with; however, up to 1,000 members may join the VC/OAVM session on a first-come-first-served basis, excluding large shareholders, promoters, and institutional investors who have unrestricted access.

Financial Context

The AGM follows strong financial results for FY26, where consolidated revenue grew 16% to ₹252,285 million and profit after tax rose 33% to ₹20,027 million. Consolidated EBITDA increased 25% to ₹37,693 million. Return on Capital Employed (ROCE) improved from 20% in FY24 to 23.7% in FY26. The company maintains credit ratings of ICRA AAA Stable, CRISIL AA+ Positive, and India Rating IND AA+/Positive.

What the Numbers Show

The decision to raise ₹7,500 million via NCDs alongside a significant dividend payout indicates a balanced approach to capital allocation. While the company generates substantial cash flows, evidenced by the 33% rise in PAT, the debt issuance supports ongoing expansion without diluting equity. The reappointment of key leadership during a major structural change like the Healthtech demerger suggests management prioritizes stability and strategic continuity.